Corcept Therapeutics (CORT) Income towards Parent Company (2010 - 2026)

Corcept Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$31.8 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 254.8% year-over-year to -$31.8 million; the TTM figure through Mar 2026 stood at $47.3 million (down 64.67% YoY), while the FY2025 annual figure was $99.7 million, down 29.43% from the prior year.
• Income towards Parent Company came in at -$31.8 million for Q1 2026 at Corcept Therapeutics, down from $24.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $47.2 million in Q3 2024 to a low of -$31.8 million in Q1 2026.
• A 5-year average of $24.5 million and a median of $27.5 million in 2023 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company surged 89.07% in 2023 and plunged 254.8% in 2026, its largest moves.
• Corcept Therapeutics' Income towards Parent Company stood at $16.6 million in 2022, then jumped by 89.07% to $31.4 million in 2023, then decreased by 2.06% to $30.7 million in 2024, then retreated by 21.0% to $24.3 million in 2025, then tumbled by 230.77% to -$31.8 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$31.8 million, $24.3 million, and $19.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison